News

Carilion CEO Nancy Howell Agee to Retire

Nancy Howell Agee, who led Carilion through more than a decade of transformative change, will step down as CEO Sept. 30. Steve Arner, who was promoted to president in May 2023, will succeed Agee and become president and CEO Oct. 1.

The leadership transition comes after Agee’s long and distinguished career at Carilion, beginning as a nurse in 1973. She was named Carilion’s president and CEO in 2011, becoming the health system’s seventh – and only female — top executive.

Agee earned national recognition for reorganizing Carilion as a fully integrated, physician-led clinic that includes a medical school and research institute with Virginia Tech, and served as chair of the American Hospital Association’s Board of Trustees in 2018.

She will serve as CEO emeritus through September 2025 and focus on philanthropy, growing Carilion’s partnerships and continuing to develop the health system’s reputation statewide and nationally.

Steve is a strong and capable leader whose commitment to our mission and deep knowledge of our entire organization make him well-suited for the CEO role,” said James Hartley, chairman of Carilion Clinic’s board of directors.

Arner has served as chief operating officer since 2012. He spearheaded more than $500 million in facilities investments, including the Crystal Spring Tower addition to Carilion Roanoke Memorial Hospital, on track for completion in 2025, and the recently opened Carilion Children’s and Mental Health facilities at Tanglewood. During the Covid-19 pandemic, he led the health system’s response, while also serving as chair of the Virginia Hospital and Healthcare Association.

“Carilion today is a nationally ranked academic health system that provides an extraordinary range of services, from primary care to the most advanced, complex care,” said Arner. “In some respects, it’s a far different organization than the one I joined more than 25 years ago. What has remained the same since the day I started is Carilion’s laser-like focus on its mission and our community, and I look forward to continuing on the path to growth and collaboration.”

Hartley added, “Carilion and our community have been the fortunate beneficiaries of Nancy’s talents for more than 50 years. I’m grateful to her for her continued service, and I’m grateful to Steve for advancing us to our next chapter.”

Read more here.

Recent News

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …

10/20/2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …

10/16/2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …